



Beleave Receives Purchase Order from Ontario Cannabis Store

Toronto, ON— August 24, 2018 – Beleave Inc. (CSE: BE) (OTCQX: BLEVF) (“**Beleave**” or the “**Company**”) is proud to announce that it has received its first purchase order from the Ontario Cannabis Store (“OCS”). This makes it one of the very first suppliers to support the sale of recreational cannabis in the province of Ontario.

“This marks the end of a great week for Beleave that started with our selection as an official supplier to the OCS just a few days ago,” said Beleave CEO, Andrew Wnek. “Being chosen to fulfill the first round of purchase orders for the province is a testament to our preparedness and operational discipline as an organization. It is the culmination of months and months of work by all our teams, and it’s this work ethic that we plan to bring to all our relationships with regulators and consumers across the country.”

This announcement comes just five days after the Company was chosen by the OCS as an official supplier. The Company worked closely with OCS over the summer to finalize the distribution and sales agreement to provide its products to the Ontario market.

Beleave will package and sell its cannabis products under the Seven Oaks brand at launch. The purchase order is larger than Beleave’s initial projections, but the Company is prepared to meet the higher demand and will fulfill the order in time for recreational sales to begin online on October 17, 2018.

The Company anticipates that this will be the first of many orders to come. Beleave is grateful for its partnership with the OCS and is committed to working with them in the future to ensure professional and responsible access for Ontario residents.

ABOUT BELEAVE INC.

Beleave is a biotech company who’s wholly-owned subsidiary Beleave Cannabis Corp. is licensed to cultivate and sell medical cannabis and produce cannabis oils and extracts pursuant to Health Canada’s Access to Cannabis for Medical Purpose Regulations. Beleave has developed a network of medical cannabis clinics under the Medi-Green banner and has applied for various patents to broaden its strong research focused foundation.

Investor Relations Contact

Richard Oyelowo
Phone : (416) 712 - 9402
Email : royelowo@storyboardcommunications.com

Media Relations Contact

Grant McLeod
SVP, Regulatory Affairs and General Counsel
Phone : (416) 910 - 3401
Email : grant@beleave.com

Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.

